Intermittent Claudication

Peripheral artery disease (PAD) is atherosclerotic narrowing of the lower-limb arteries. Intermittent claudication (IC) is its classic symptomatic presentation — exertional muscle discomfort, cramping, or fatigue that is reproducibly brought on by a consistent amount of walking and reproducibly relieved by a short period of rest, typically within about 10 minutes.^[1] PAD is not always symptomatic in this classic way — it can be entirely asymptomatic, or it can present at the severe end of its spectrum as chronic limb-threatening ischemia or acute limb ischemia (see Recognize the Condition).

The single most important concept in managing IC is that it has 2 distinct, simultaneously pursued goals that are not interchangeable. The primary goal is cardiovascular risk reduction: PAD is not a localized leg problem but a marker of systemic atherosclerosis, and a patient with symptomatic PAD carries a risk of myocardial infarction, stroke, and cardiovascular death comparable to a patient with established coronary artery disease — antiplatelet therapy, high-intensity statin therapy, blood pressure and glycemic control, and smoking cessation address this risk directly and are indicated in essentially every patient regardless of how mild the leg symptoms are. The secondary goal is symptom and functional improvement — increasing pain-free and maximal walking distance and preserving mobility and quality of life — addressed through supervised exercise therapy and, when needed, symptom-directed pharmacotherapy. Treating only the leg symptoms while leaving cardiovascular risk unaddressed is a common and consequential error.^[2]

Typical presentation

Exertional discomfort, cramping, tightness, or fatigue in a specific muscle group — most often the calf, but sometimes the thigh or buttock with more proximal (aortoiliac) disease — brought on reproducibly after walking a consistent distance and resolving reproducibly with a short period of standing rest, usually within about 10 minutes. The pain does not require sitting down or a change in posture to resolve, and it recurs at a similar distance each time walking resumes (see Assessment & Diagnosis for how this differs from other causes of exertional leg pain).

Classifying walking-distance severity

Document the walking distance or time to onset of claudication at every assessment — it is both a diagnostic clue and the outcome measure used to track response to treatment:

• Mild: claudication onset after more than 1 city block (roughly 100 m, or about 300 ft).
• Moderate: claudication onset between one-half and 1 city block.
• Severe: claudication onset before one-half of a city block.

The spectrum of PAD presentations

Staging systems

Two staging systems are used interchangeably in vascular practice and in referral communication — know both:

Fontaine III/IV and Rutherford 4-6 together define chronic limb-threatening ischemia.^[2]

Modifiable

• Tobacco use, active or secondhand — the single strongest modifiable risk factor for PAD.
• Diabetes mellitus.
• Dyslipidemia.
• Hypertension.
• Physical inactivity.
• Short sleep duration and daytime napping — an emerging, independently associated risk factor.

Nonmodifiable

• Age — risk rises steadily with age.
• Family history of premature cardiovascular disease.

Associated conditions that raise the likelihood PAD is already present

• Known coronary artery disease or prior myocardial infarction.
• Known cerebrovascular disease or prior TIA/stroke.
• Chronic kidney disease.

Differentiating exertional leg pain: 4 common causes

History

• Cardiovascular risk factors and associated conditions: angina or prior MI, diabetes mellitus, dyslipidemia, hypertension, smoking, prior TIA or stroke.
• Walking distance or time to claudication onset, classified as mild/moderate/severe (see Recognize the Condition) — both diagnostic and the baseline against which treatment response is measured.
• Duration of symptoms — collateral circulation typically takes 6-12 months to develop after claudication onset, directly relevant to counselling a patient on how long exercise therapy needs to run before being judged ineffective (see Non-Pharmacologic Treatment).
• Any rest pain, non-healing wound, or colour change in the foot or toes — these suggest progression toward chronic limb-threatening ischemia (see Red Flags & Refer).

Physical examination

• Signs of hypertension, dyslipidemia, diabetes, or atherosclerosis elsewhere — an abdominal aortic aneurysm, carotid or femoral bruits, or signs of heart failure.
• Peripheral pulses — femoral, popliteal, posterior tibial, and dorsalis pedis. A diminished or absent pulse suggests arterial obstruction; conversely, normal pulses and the absence of a bruit make significant obstruction less likely.
• Signs of acute arterial occlusion — sudden, continuous pain; a pale, cool, or mottled limb; and swollen, stiff, tender muscle — is a red flag requiring emergency referral, not an outpatient work-up (see Red Flags & Refer).
• Signs of severe chronic obstruction — rest pain, dependent rubor, cyanosis, muscle atrophy, or trophic ulcers — suggest chronic limb-threatening ischemia (see Red Flags & Refer).

Laboratory testing

• Fasting glucose (or HbA1c), serum creatinine, and a fasting lipid profile.
• Hemoglobin, hematocrit, and platelet count — anemia can worsen claudication symptoms independent of arterial disease.
• Elevated inflammatory markers (e.g. C-reactive protein) or D-dimer are associated with higher short-term cardiovascular and all-cause mortality risk and support a more intensive risk-reduction approach, though they are not required to make the diagnosis.

Ankle-brachial index — the primary diagnostic test

The ankle-brachial index (ABI) is the ratio of the higher systolic pressure at the ankle (dorsalis pedis or posterior tibial artery) to the higher systolic pressure in the arm (brachial artery), measured with a blood pressure cuff and a handheld Doppler device.^[2]

Further testing

• Toe-brachial index (TBI): use when the ABI is noncompressible (over 1.40) — common in diabetes and chronic kidney disease, where arterial calcification prevents the cuff from compressing the vessel — since digital arteries stay compressible even when the tibial arteries do not.^[3]
• Exercise (post-exercise) ABI: when the resting ABI is normal (1.00-1.40) but the history strongly suggests claudication, a treadmill test with ABI measured immediately after exercise can unmask a significant pressure drop that confirms the diagnosis.
• 6-minute walk test: a simple, reproducible functional measure of walking capacity, useful both for diagnosis in equivocal cases and for tracking response to exercise therapy over time.^[3]
• Duplex ultrasound, CT angiography, or MR angiography: reserved for patients being considered for revascularization — not needed to diagnose or medically manage claudication.
• Invasive angiography: reserved for patients with signs of severe limb ischemia (rest pain, muscle atrophy, cyanosis, non-healing ischemic ulcers, or gangrene) being worked up for possible angioplasty or surgical revascularization.

When testing is not indicated

Advanced imaging (CT angiography, MR angiography, or invasive angiography) is not indicated simply to confirm a diagnosis of claudication that is already clear from history, exam, and ABI — reserve it for patients in whom revascularization is genuinely being considered, or those with signs of severe or critical limb ischemia.

• Reduce the risk of myocardial infarction, stroke, and cardiovascular death — the primary treatment goal in PAD, addressed by cardiovascular risk-reduction therapy (see below).
• Reduce major adverse limb events — progression to chronic limb-threatening ischemia, need for revascularization, or amputation.
• Achieve the statin, blood pressure, and glycemic targets defined in the Dyslipidemias, Hypertension, and Diabetes Mellitus chapters.
• Achieve complete tobacco cessation.
• Increase pain-free and maximal walking distance and time to claudication onset.
• Increase capacity for regular dynamic leg exercise.
• Improve mobility and quality of life, and reduce functional decline.

Supervised exercise therapy — the single most effective symptom-directed intervention

Supervised exercise therapy (SET) is a structured, supervised walking program delivered in a hospital or outpatient facility under the direction of a physician or advanced-practice provider, typically implemented day-to-day by a clinical exercise physiologist or nurse. It produces a larger, more consistent improvement in walking distance than any single drug used for claudication, and it should be offered at the time of diagnosis — not reserved as a last resort after drug therapy fails.^[6]

• Format: interval (walk-rest-walk) training — walk to moderate-to-severe claudication pain, then rest until the pain resolves, and repeat for the full session.
• Session length: 30-45 minutes of accumulated walking time per session.
• Frequency: at least 3 times per week.
• Minimum duration: 12 weeks; benefit continues to accrue with a longer program.

Ideally, a 3-month period of supervised therapy is followed by transition to a home- or community-based walking program to maintain the gain. Where a hospital-based supervised program is not accessible, a structured home- or community-based program — walking to near-maximal claudication pain, 3 or more times weekly — is a reasonable alternative, though it produces a smaller average benefit than a truly supervised program.^[6] Smartphone-based tracking and other adherence-support technology are emerging tools to help sustain a home program.

Set expectations on timing

Tell the patient explicitly, when exercise therapy is started, that dynamic leg exercise sustained for 6-12 months allows collateral circulation to develop around the arterial narrowing, and that continuing regular exercise for 24-36 months slows longer-term functional decline — patients who are not told this timeline often stop adhering before a real effect has had time to appear.

Foot and skin care

• Daily foot inspection, particularly in a patient who also has diabetes or reduced sensation, since early ischemic or neuropathic changes are easy to miss without a deliberate check.
• Well-fitting, protective footwear, and prompt attention to any new wound, blister, or colour change rather than waiting for it to resolve on its own.
• Avoid activities and footwear likely to cause minor trauma — even a minor injury can progress to a non-healing ulcer in significant PAD.

Non-drug management of contributing conditions

Address diabetes, hypertension, dyslipidemia, and obesity with the non-pharmacologic measures described in their own chapters (Diabetes Mellitus, Hypertension, Dyslipidemias, Obesity) — these run in parallel with, not instead of, PAD-specific management.

Revascularization — a procedural option, not a default early step

Revascularization (angioplasty or surgical bypass) does not by itself alter long-term limb outcomes for claudication and does not reliably provide a durable functional or quality-of-life advantage over optimal medical therapy and supervised exercise for most patients with claudication alone.^[1] Reserve it for patients with lifestyle-limiting symptoms despite an adequate trial of supervised exercise and optimized medical therapy, or for chronic limb-threatening/acute limb ischemia, rather than offering it as an early or default option for claudication (see Treatment Failure & Next Step).

Pregnancy

Symptomatic PAD is uncommon in patients of reproductive age, since it reflects long-standing atherosclerosis, but the same principles apply if it occurs. Contraindicated in pregnancy statins — see Dyslipidemias. Cilostazol and pentoxifylline are not recommended in pregnancy given insufficient safety data and an animal-study signal; avoid unless the potential benefit clearly outweighs the risk, in consultation with obstetric and vascular specialists. Low-dose ASA at the doses used for PAD is generally considered compatible with pregnancy, but confirm the indication is still needed. ACE inhibitors and ARBs are contraindicated in pregnancy — see Hypertension.

Breastfeeding

Statins are not recommended during breastfeeding — see Dyslipidemias. Cilostazol has been detected in animal milk; discontinue breastfeeding or discontinue the drug. Pentoxifylline and its breakdown products pass into human breast milk; weigh how important the drug is to the mother against stopping breastfeeding or stopping the medication. Low-dose ASA is generally considered compatible with breastfeeding.

Older adults

PAD becomes more common and more severe with age. Older adults are also more likely to have unrecognized heart failure or reduced cardiac reserve — confirm the absence of heart failure explicitly before starting cilostazol, and reconfirm at every refill rather than assuming a stable history. Bleeding risk from any antiplatelet or dual pathway inhibition regimen also rises with age — weigh this explicitly before adding rivaroxaban to ASA in an older patient.

Diabetes

Diabetic peripheral neuropathy can blunt or mask the pain of ischemia, so a patient with diabetes may present later, with a more advanced ulcer or with painless tissue loss rather than classic claudication — keep a lower threshold for foot examination and ABI testing in this population. Arterial calcification frequently makes the ABI falsely elevated (noncompressible, over 1.40) in diabetes — use a toe-brachial index instead when this occurs (see Assessment & Diagnosis). An SGLT2 inhibitor is a preferred glucose-lowering choice in a patient with type 2 diabetes and PAD given its independent cardiovascular and limb benefit — see Diabetes Mellitus and Diabetes Mellitus - Chronic Complications for dosing.

Renal impairment

Avoid rivaroxaban-based dual pathway inhibition in significant renal impairment — confirm current creatinine clearance against the product-specific threshold before starting or continuing it. No dose adjustment is required for cilostazol in mild-to-moderate renal impairment; it has not been studied in severe renal impairment. Pentoxifylline requires a reduced dose in severe renal impairment (creatinine clearance under 30 mL/min) — see Drug Tables.

• Reassess walking distance/time to claudication onset at each follow-up, using the same method as at baseline (patient-reported distance, a standardized walking-impairment questionnaire, or a 6-minute walk test) — the primary way to judge whether symptom-directed therapy is working.
• Repeat the ABI if the clinical picture changes, or to document a new baseline after a significant change in therapy or after revascularization.
• Follow the lipid-panel, blood-pressure, and glycemic monitoring schedules in Dyslipidemias, Hypertension, and Diabetes Mellitus.
• Reassess tobacco-use status and offer cessation support at every visit until the patient has fully quit.
• Inspect the feet at every visit in a patient with diabetes or any sign of reduced sensation, and ask specifically about any new wound.
• At every cilostazol prescription or refill, ask specifically about new or worsening shortness of breath, swelling, or weight gain, and confirm there is still no diagnosis of heart failure.
• Reassess cilostazol or pentoxifylline benefit at 12 weeks; discontinue if there has been no meaningful improvement in walking distance at an adequate dose and duration.
• Monitor for bleeding at every visit in a patient on dual pathway inhibition or any antiplatelet/anticoagulant combination.

1. Confirm adherence to, and correct technique for, the supervised or home exercise program before concluding pharmacotherapy has failed — many apparent treatment failures are really an inadequate exercise trial.
2. Confirm cardiovascular risk-reduction therapy is actually optimized — statin intensity, antiplatelet therapy, blood pressure, glycemic control, and smoking status — undertreated risk factors are a common, correctable cause of a patient feeling that nothing is working.
3. If cilostazol has been used at 100 mg PO BID for a full 12 weeks without meaningful benefit, confirm there is still no heart failure diagnosis, then discontinue — continuing an ineffective drug only adds risk without benefit.
4. If cilostazol cannot be used or accessed, consider a trial of pentoxifylline while setting realistic, modest expectations, or refer for vascular assessment sooner if symptoms are significantly limiting.
5. If functional-limiting claudication persists despite an adequate trial of supervised exercise and appropriate pharmacotherapy, refer for vascular assessment to evaluate candidacy for revascularization.
6. If rest pain, non-healing ulceration, gangrene, or any feature of acute limb ischemia develops at any point, refer urgently to vascular surgery immediately — this is never managed by titrating oral therapy further (see Red Flags & Refer).

• Focusing on leg symptoms alone and neglecting cardiovascular risk reduction — the primary treatment goal in PAD is preventing MI, stroke, and cardiovascular death, not just improving walking distance.
• Prescribing or continuing cilostazol without explicitly asking about heart failure at every new prescription and every refill — this is an absolute, not relative, contraindication.
• Reaching for a drug before offering supervised exercise therapy, which is the single most effective symptom-directed intervention and is often underutilized relative to its effectiveness.
• Treating pentoxifylline as if it remains a guideline-preferred option — current evidence has moved decisively away from it, and it is now a distant, honestly-framed alternative rather than routine therapy.
• Avoiding beta-blockers in PAD out of outdated concern that they worsen claudication — current evidence shows they do not meaningfully impair walking capacity and are appropriate when otherwise indicated.
• Trusting a normal or high ankle-brachial index in a patient with diabetes or chronic kidney disease without considering that arterial calcification can make the result falsely elevated (noncompressible) — a toe-brachial index is needed in that situation.
• Escalating oral pharmacotherapy in a patient with new rest pain, a non-healing ulcer, or signs of acute limb ischemia instead of referring urgently for vascular assessment.
• Missing the opportunity to start an SGLT2 inhibitor in a patient who has both type 2 diabetes and PAD, given its independent benefit for major adverse limb events.
• Setting no explicit timeline expectation for exercise therapy — patients who are not told that collateral circulation takes 6-12 months to develop often stop adhering before a real effect has appeared.

How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Antiplatelet Agents

Lipid-Lowering Therapy (summary — see Dyslipidemias for the complete class table)

Every patient with symptomatic PAD is treated at high intensity, regardless of baseline LDL — the same threshold used for established coronary artery disease.

Symptom-Directed Pharmacotherapy

Neither agent below reduces cardiovascular events or mortality — both are used only to improve walking distance, alongside (never instead of) the cardiovascular risk-reduction therapy above. Naftidrofuryl, used for this purpose in some European countries, is not available in Canada and is not discussed further here.

Evidence note: Dual pathway inhibition dosing is cross-checked against the current ACC/AHA lower-extremity PAD guideline.^[2] Cilostazol's dosing, heart-failure contraindication, and Canadian availability status are cross-checked against the current Canadian Cardiovascular Society PAD guideline and the independent Health Canada regulatory record.^[1]